Related Experiment Video
Updated: Nov 12, 2025
07:18
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
7.2K
Analysis of Immune Gene Expression Subtypes Reveals Osteosarcoma Immune Heterogeneity
Ben Wan1, Renxian Wang1, Jingjun Nie1
1Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Traumatology and Orthopaedics, Beijing JiShuiTan Hospital, Beijing 100035, China.
Journal of Oncology
|March 17, 2021
Summary
Osteosarcoma patients were classified into five immune subtypes, revealing significant heterogeneity. This discovery may enable personalized immunotherapies for osteosarcoma (OS) by understanding distinct tumor-immune microenvironments.
Area of Science:
- Immunology
- Oncology
- Bioinformatics
Background:
- Osteosarcoma (OS) exhibits poor immunotherapy response due to complex tumor-immune microenvironments.
- Understanding immune heterogeneity is crucial for improving OS treatment outcomes.
Purpose of the Study:
- To identify and validate distinct immune subtypes in osteosarcoma patients.
- To explore the relationship between immune subtypes and clinical outcomes, genetic aberrations, and immune cell profiles.
Main Methods:
- Clustering of patients based on immune gene expression profiles from TARGET and GEO databases.
- Assessed reproducibility and association with molecular characteristics using ANOVA.
- Utilized graph structure learning for dimensionality reduction and patient distribution visualization.
Main Results:
- Identified five reproducible immune subtypes in 87 OS samples, each linked to different clinical outcomes.
- Observed distinct patterns in genetic aberrations, immune cell infiltration, and cytokine profiles across subtypes.
- Revealed significant intracluster heterogeneity and a continuous immune spectrum among OS patients.
Conclusions:
- The five identified immune subtypes highlight the significant immune heterogeneity in osteosarcoma.
- These subtypes offer a potential framework for developing individualized immunotherapy strategies for OS patients.
